1353 related articles for article (PubMed ID: 28933516)
21. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.
Crossingham I; Turner S; Ramakrishnan S; Fries A; Gowell M; Yasmin F; Richardson R; Webb P; O'Boyle E; Hinks TS
Cochrane Database Syst Rev; 2021 May; 5(5):CD013518. PubMed ID: 33945639
[TBL] [Abstract][Full Text] [Related]
22. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults.
Chauhan BF; Chartrand C; Ducharme FM
Cochrane Database Syst Rev; 2013 Feb; (2):CD009611. PubMed ID: 23450606
[TBL] [Abstract][Full Text] [Related]
23. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children.
Chauhan BF; Chartrand C; Ni Chroinin M; Milan SJ; Ducharme FM
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD007949. PubMed ID: 26594816
[TBL] [Abstract][Full Text] [Related]
24. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
Respir Med; 2019; 154():69-75. PubMed ID: 31220806
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
26. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma.
Evans DJ; Kew KM; Anderson DE; Boyter AC
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD011437. PubMed ID: 26196545
[TBL] [Abstract][Full Text] [Related]
27. Macrolides versus placebo for chronic asthma.
Undela K; Goldsmith L; Kew KM; Ferrara G
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD002997. PubMed ID: 34807989
[TBL] [Abstract][Full Text] [Related]
28. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children.
Kew KM; Flemyng E; Quon BS; Leung C
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD007524. PubMed ID: 36161875
[TBL] [Abstract][Full Text] [Related]
29. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
[TBL] [Abstract][Full Text] [Related]
30. Exploring the risk of infection events in patients with asthma receiving
Giossi R; Pani A; Schroeder J; Scaglione F
Heliyon; 2024 Jan; 10(1):e23725. PubMed ID: 38268596
[TBL] [Abstract][Full Text] [Related]
31. Anti-cytokine targeted therapies for ANCA-associated vasculitis.
Bala MM; Malecka-Massalska TJ; Koperny M; Zajac JF; Jarczewski JD; Szczeklik W
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD008333. PubMed ID: 32990324
[TBL] [Abstract][Full Text] [Related]
32. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
33. Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids.
Ahmad S; Kew KM; Normansell R
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011306. PubMed ID: 26089258
[TBL] [Abstract][Full Text] [Related]
34. Vilanterol and fluticasone furoate for asthma.
Dwan K; Milan SJ; Bax L; Walters N; Powell C
Cochrane Database Syst Rev; 2016 Sep; 9(9):CD010758. PubMed ID: 27582089
[TBL] [Abstract][Full Text] [Related]
35. Sublingual immunotherapy for asthma.
Fortescue R; Kew KM; Leung MST
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD011293. PubMed ID: 32926419
[TBL] [Abstract][Full Text] [Related]
36. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials.
Liu Y; Zhang S; Li DW; Jiang SJ
PLoS One; 2013; 8(3):e59872. PubMed ID: 23544105
[TBL] [Abstract][Full Text] [Related]
38. Interventions to improve adherence to inhaled steroids for asthma.
Normansell R; Kew KM; Stovold E
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012226. PubMed ID: 28417456
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials.
Liu T; Wang F; Wang G; Mao H
Front Med; 2018 Jun; 12(3):340-349. PubMed ID: 29086236
[TBL] [Abstract][Full Text] [Related]
40. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
